BRPI1006790B8 - método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico - Google Patents

método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico

Info

Publication number
BRPI1006790B8
BRPI1006790B8 BRPI1006790A BRPI1006790A BRPI1006790B8 BR PI1006790 B8 BRPI1006790 B8 BR PI1006790B8 BR PI1006790 A BRPI1006790 A BR PI1006790A BR PI1006790 A BRPI1006790 A BR PI1006790A BR PI1006790 B8 BRPI1006790 B8 BR PI1006790B8
Authority
BR
Brazil
Prior art keywords
foam
composition
developing
skin
liquid pharmaceutical
Prior art date
Application number
BRPI1006790A
Other languages
English (en)
Inventor
G Seigfried Bernd
Original Assignee
Mika Pharma Ges Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mika Pharma Ges Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh filed Critical Mika Pharma Ges Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh
Publication of BRPI1006790A2 publication Critical patent/BRPI1006790A2/pt
Publication of BRPI1006790B1 publication Critical patent/BRPI1006790B1/pt
Publication of BRPI1006790B8 publication Critical patent/BRPI1006790B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)

Abstract

método para desenvolver uma composição líquida a ser aplicada na pele como uma espuma e uma composição que pode ser aplicada topicamente. a invenção refere-se a um método para desenvolver uma composição farmacêutica líquido a ser aplicada na pele como uma espuma e a uma composição correspondente que pode ser espumada e que tem no mínimo um ingrediente farmacêutico ativo, e no mínimo um agente de espumação. o volume da espuma e a estabilidade da espuma são determinados de acordo com um método de medição sita padronizado. o agente de espumação, o solvente, e o ingrediente farmacêutico ativo são variados com respeito ao tipo químico e/ou á concentração dos mesmos até a espuma produzida desde modo pelo método de medição sita ter um volume de espuma de no mínimo 400 ml e uma estabilidade da espuma tal que depois ainda tem no mínimo 50% do volume da espuma que existe originalmente depois da espuma ser produzida.
BRPI1006790A 2009-07-24 2010-07-16 método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico BRPI1006790B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009034603 2009-07-24
DE102009034603.1 2009-07-24
PCT/DE2010/000818 WO2011009436A2 (de) 2009-07-24 2010-07-16 Verfahren zur entwicklung einer als schaum auf die haut zu applizierende flüssige zusammensetzung sowie eine topisch applizierbare zusammensetzung

Publications (3)

Publication Number Publication Date
BRPI1006790A2 BRPI1006790A2 (pt) 2017-05-02
BRPI1006790B1 BRPI1006790B1 (pt) 2020-10-20
BRPI1006790B8 true BRPI1006790B8 (pt) 2021-05-25

Family

ID=43384132

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006790A BRPI1006790B8 (pt) 2009-07-24 2010-07-16 método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico

Country Status (14)

Country Link
US (4) US20110269704A1 (pt)
EP (1) EP2387391B1 (pt)
JP (1) JP2013500239A (pt)
BR (1) BRPI1006790B8 (pt)
CA (1) CA2752849C (pt)
DE (1) DE102010027315A1 (pt)
ES (1) ES2622097T3 (pt)
HR (1) HRP20170376T1 (pt)
MX (1) MX2011008660A (pt)
PL (1) PL2387391T3 (pt)
PT (1) PT2387391T (pt)
RU (1) RU2532027C2 (pt)
SI (1) SI2387391T1 (pt)
WO (1) WO2011009436A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110269704A1 (en) 2009-07-24 2011-11-03 Seigfried Bernd G Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically
IN2012DN06581A (pt) 2010-03-17 2015-10-23 Novaliq Gmbh
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DE102010055252A1 (de) * 2010-12-20 2012-06-21 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Verfahren zur Entwicklung einer als Schaum auf die Haut zu applizierende flüssige Zusammensetzung sowie eine topisch applizierbare Zusammensetzung
CA2834862C (en) * 2011-05-25 2019-12-17 Novaliq Gmbh Pharmaceutical composition for administration to nails
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
BR112014017719A8 (pt) 2012-01-23 2017-07-11 Novaliq Gmbh Composições de proteína estabilizada baseadas em alcanos semifluorados
US20130309215A1 (en) * 2012-05-15 2013-11-21 Mika Pharma Gesellschaft Fur Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmaceutical composition
DE102013004199A1 (de) * 2012-05-15 2013-11-21 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmazeutische Zusammensetzung
PL3181119T3 (pl) 2012-09-12 2020-01-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki
DE202013012742U1 (de) 2012-09-12 2019-01-22 Novaliq Gmbh Zusammensetzungen umfassend Mischungen aus semifluorierten Alkanen
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
AU2015368402A1 (en) * 2014-12-24 2017-07-27 Pola Pharma Inc. External composition for screen foamers
KR102154415B1 (ko) 2015-09-30 2020-09-10 노바리크 게엠베하 부분불소화 화합물
ES2743502T3 (es) 2015-09-30 2020-02-19 Novaliq Gmbh Compuestos semifluorados y sus composiciones
RU2609197C1 (ru) * 2015-12-15 2017-01-30 Иштимер Шагалиевич Хурамшин Раствор для декальцинации при лечении заболеваний опорно-двигательного аппарата
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
MX2019003364A (es) 2016-09-23 2019-10-02 Novaliq Gmbh Composiciones oftalmicas que comprenden ciclosporina.
ES2957559T3 (es) 2017-04-21 2024-01-22 Dermaliq Therapeutics Inc Composiciones de yodo
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
RU2659418C1 (ru) * 2017-08-24 2018-07-02 Закрытое Акционерное Общество "Производственная Фармацевтическая Компания Обновление" Антибактериальная композиция для доставки Грамицидина С к очагу местного воспаления, способ приготовления антибактериальной композиции для доставки Грамицидина С к очагу местного воспаления, способ доставки Грамицидина С к очагу местного воспаления
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
RU2697829C2 (ru) * 2017-11-01 2019-08-21 Общество с ограниченной ответственностью "Технофарм" Фармацевтическая композиция, содержащая нитрофурал, в форме шипучих таблеток (варианты)
CN112135603B (zh) 2018-03-02 2024-04-16 诺瓦利克有限责任公司 包含奈必洛尔的药物组合物
CN112839620A (zh) 2018-09-27 2021-05-25 诺瓦利克有限责任公司 脂质屏障修复剂
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
JP7500550B2 (ja) 2018-10-12 2024-06-17 ノバリック ゲーエムベーハー 乾性眼疾患の治療のための眼科用組成物
RU2696568C1 (ru) * 2019-03-20 2019-08-05 Общество с ограниченной ответственностью "Технофарм" Фармацевтическая композиция, содержащая нитрофурал, в форме шипучих таблеток (варианты)
RU2742411C1 (ru) * 2020-10-08 2021-02-05 Георгий Сергеевич Немов Противопсориатическая косметическая композиция в виде геля
EP4359445A1 (en) * 2021-06-21 2024-05-01 Joint Stock Company "Biocad" Isolated bispecific antibody that specifically binds to cd47 and pd-l1
CN114409734B (zh) * 2022-01-25 2023-05-12 四川大学华西医院 一种可诱导局部***生物矿化的自组装短肽及其制得的长效局部麻醉和镇痛药物制剂

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510561A (en) * 1893-12-12 John abell
JPS5210457B2 (pt) * 1973-10-24 1977-03-24
JPS5473135A (en) * 1977-11-24 1979-06-12 Kashiwa Kagaku Kogyo Kk Bubble type permanent wave agent
DE3585967D1 (de) * 1984-03-08 1992-06-11 Phares Pharma Holland Liposombildende zusammensetzung.
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
JPH01242521A (ja) * 1988-03-23 1989-09-27 Nikko Kemikaruzu Kk 経皮吸収性を高めた消炎鎮痛薬組成物
DE3824353A1 (de) * 1988-07-19 1990-01-25 Paz Arzneimittelentwicklung Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren
US4975425A (en) * 1989-03-16 1990-12-04 Mobay Corporation Pesticidal and herbicidal foams
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
KR920703410A (ko) 1990-11-07 1992-12-17 야마구찌 히사기찌 거품 분출 펌프 용기
IT1247529B (it) * 1991-04-24 1994-12-17 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale
ES2122975T3 (es) 1991-07-05 1999-01-01 Rhone Poulenc Rorer Gmbh Composicion fosfolipidica.
DE4140183C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140172C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140179C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Ibuprofen enthaltendes Arzneimittel
DE4216756C2 (de) * 1992-05-21 1994-08-25 Pharmatrans Sanaq Ag 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
JPH0669161U (ja) 1993-03-05 1994-09-27 大和製罐株式会社 ポンプ式泡出し容器
DE4313402A1 (de) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung
US5580491A (en) * 1993-07-13 1996-12-03 Cornell Research Foundation, Inc. Foamable whey protein composition
DE19536245A1 (de) 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung
DE4436352A1 (de) * 1994-10-12 1996-04-18 Kay Brune Verfahren zur diagnostischen Beurteilung und Verlaufskontrolle sowie Arzneimittel zur Therapie von Schockzuständen beim Menschen
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
DE19520659A1 (de) 1995-06-09 1996-12-12 Mika Pharma Ges Fuer Die Entwi Pharmazeutische Zubereitung zur Therapie und/oder Prophylaxe von durch Viren bedingten Erkrankungen der Haut und/oder der Schleimhaut
WO1998002184A1 (de) 1996-07-13 1998-01-22 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Topische phospholipidhaltige aciclovirzubereitung
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
DE19740095C2 (de) 1997-09-12 2000-06-08 Cognis Deutschland Gmbh Verfahren zum Bestimmen der Schaumeigenschaften von Tensiden
AU9281698A (en) 1997-10-01 1999-04-23 Wakamoto Pharmaceutical Co., Ltd. O/w emulsion compositions
ATE267613T1 (de) * 1998-03-05 2004-06-15 Phares Pharm Res Nv Arzneimittel und deren verwendung
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
DE19907895A1 (de) 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
DE19925810A1 (de) 1999-06-07 2000-12-14 Paz Arzneimittelentwicklung Anwendung von Verapamil und Verapamilderivaten zur Herstellung von Arzneimitteln mit Glucuronidase hemmender Wirkung
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19949922C1 (de) 1999-10-16 2001-05-31 Sita Messtechnik Gmbh Verfahren und Vorrichtung zum Messen der Schaumeigenschaften von Flüssigkeiten
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6645520B2 (en) * 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
DE10024413A1 (de) * 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10047319A1 (de) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
DE10142996A1 (de) * 2001-09-01 2003-03-27 Paz Arzneimittelentwicklung Verwendung von Wirkstoffen mit mu-Opioid-Rezeptor agonistischer Wirkung als Kombinationsarzneimittel zur Krebsbehandlung
FR2829693B1 (fr) * 2001-09-20 2004-02-27 Oreal Creme cosmetique moussante
DE10217555A1 (de) * 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
GB0323908D0 (en) * 2003-10-11 2003-11-12 Nupharm Lab Ltd Pharmaceutical foam formulation
US20050220742A1 (en) * 2004-03-31 2005-10-06 Breen Ed V Compositions and methods for maintaining eyelid hygiene
US7971659B2 (en) * 2004-05-05 2011-07-05 Clearwater International, Llc Foamer/sulfur scavenger composition and methods for making and using same
WO2006121806A1 (en) * 2005-05-10 2006-11-16 Johnson & Johnson Consumer Companies, Inc. Low-irritation compositions and methods of making the same
US20070160555A1 (en) * 2006-01-09 2007-07-12 Staudigel James A Personal care compositions containing cationically modified starch and an anionic surfactant system
US20070224153A1 (en) * 2006-03-16 2007-09-27 Librizzi Joseph J High-deposition compositions and uses thereof
ATE440598T1 (de) 2007-03-02 2009-09-15 Flamek Corp Ou Analgesische zusammensetzung von topisch angewendeten, nichtsteroiden und entzündungshemmenden arzneimitteln und opioiden
BRPI0809164B8 (pt) * 2007-03-22 2023-02-28 Berg Llc Composição para administração tópica e composição farmacêutica compreendendo a referida composição
EP1975224A1 (en) 2007-03-30 2008-10-01 Johnson & Johnson Consumer France SAS Mild, foaming cleansing composition
PL2020221T3 (pl) 2007-06-19 2012-07-31 Neubourg Skin Care Gmbh & Co Kg Kremy DMS (Derma Membrane Structure) w postaci pianki
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
PL2244703T3 (pl) 2007-12-21 2012-05-31 Horizon Pharma Ag Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
PL2172117T3 (pl) * 2008-09-25 2012-04-30 Nestec Sa Zmniejszenie cierpkości w kompozycjach zawierających fenolowe związki
MX2011004454A (es) 2008-10-31 2011-08-15 Moberg Derma Ab Composicion topica que comprenden una combinacion de al menos dos agentes mejoradores de penetracion.
US20110269704A1 (en) 2009-07-24 2011-11-03 Seigfried Bernd G Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically
US20130309215A1 (en) * 2012-05-15 2013-11-21 Mika Pharma Gesellschaft Fur Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmaceutical composition

Also Published As

Publication number Publication date
PT2387391T (pt) 2017-04-20
ES2622097T3 (es) 2017-07-05
JP2013500239A (ja) 2013-01-07
PL2387391T3 (pl) 2017-09-29
EP2387391A2 (de) 2011-11-23
US20180104185A1 (en) 2018-04-19
SI2387391T1 (sl) 2017-04-26
WO2011009436A3 (de) 2011-09-15
US20110269704A1 (en) 2011-11-03
US20160022579A1 (en) 2016-01-28
MX2011008660A (es) 2011-09-22
BRPI1006790A2 (pt) 2017-05-02
WO2011009436A2 (de) 2011-01-27
US20110059117A1 (en) 2011-03-10
RU2011134420A (ru) 2013-02-27
RU2532027C2 (ru) 2014-10-27
US9005626B2 (en) 2015-04-14
US9693956B2 (en) 2017-07-04
WO2011009436A9 (de) 2011-03-31
HRP20170376T1 (hr) 2017-05-05
EP2387391B1 (de) 2017-01-11
CA2752849C (en) 2014-07-08
BRPI1006790B1 (pt) 2020-10-20
CA2752849A1 (en) 2011-01-27
DE102010027315A1 (de) 2011-01-27

Similar Documents

Publication Publication Date Title
BRPI1006790B8 (pt) método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico
Santos et al. Influence of penetration enhancer on drug permeation from volatile formulations
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
BRPI0417287A (pt) espuma oleosa para uso farmacêutico e cosmético
BRPI0809891C8 (pt) dispensador, produto e composições de espuma higienizante
BR112014000178A2 (pt) composições tópicas
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
BR112015023425A2 (pt) método e composição para coloração e processamento de uma amostra de urina
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
BRPI0413957A (pt) processo para preparar diterpenos solúveis em água, solução aquosa e suas aplicações
WO2012083906A3 (de) Verfahren zur entwicklung einer als schaum auf die haut zu applizierende flüssige zusammensetzung sowie eine topisch applizierbare zusammensetzung
BRPI0714399B8 (pt) composição farmacêutica líquida oral
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
CL2011000263A1 (es) Composicion de limpieza, estable, multifase, isotropica que comprende 99 a 84% por peso de una fase acuosa, incluyendo surfactante no ionico, anfotero, agente estabilizador de dispersion polimerica, y 1 a 16% por peso de vaselina; proceso para preparar dicha composicion de limpieza.
Oliveira et al. The role of vehicle interactions on permeation of an active through model membranes and human skin
AR053737A1 (es) Formulacion pediatrica de topiramato
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
IN2012DN02817A (pt)
CL2010001642A1 (es) Composicion farmaceutica topica en gel que comprende a) 0,25 a 4,5% de un agente activo para el tratamiento de la queratosis actinica, b) un agente queratoliticamente activo, c) un formador de gel, d) un solvente organico, y menos de 5% en peso de agua; util para el tratamiento de la queratosis actinica.
BRPI0907970A8 (pt) composição para tratamento dos cabelos ou pelos e método para aumentar o diâmetro dos cabelos ou pelos
BRPI0803703A2 (pt) composição pesticida
BR112018016394A2 (pt) dispositivo e processo para isolar de ácidos nucleicos de sangue total
NZ589971A (en) Emollient composition comprising glycerol, vaseline and liquid paraffin
Ioannou et al. The potential of the use of deep eutectic solvents and amino acid-based ionic liquids to enhance the chiral discrimination ability of different chiral selectors in capillary electrophoresis
Hillaert et al. Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of florfenicol

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2679 DE 10-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.